PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR, USA.\', \'Phoenix Neurological Associates, Phoenix, AZ, USA.\', \'Department of Neurology, University of Chicago, Chicago, IL, USA.\', \'Biogen, Cambridge, MA, USA.\', \'Department of Neurology, Jacobs Comprehensive MS Treatment and Research Center, Jacobs School of Medicine and Biomedical Sciences, State University of New York, 1010 Main St., 2nd floor, Buffalo, NY, 14202, USA. bw8@buffalo.edu.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1007/s40263-021-00822-z
?:doi
?:hasPublicationType
?:journal
  • CNS drugs
is ?:pmid of
?:pmid
?:pmid
  • 34228301
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.635
?:rankingScore_hIndex
  • 96
?:title
  • Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34228301>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34228301>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all